Predicting response to treatment in gastroesophageal junction adenocarcinomas: Combining clinical, imaging, and molecular biomarkers

Oncologist

Volumn 15, Issue 3, 2010, Pages 270-284

  Bain, Gillian H ^a   Petty, Russell D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Adenocarcinoma; Biomarkers; Gastroesophageal junction; Positron emission tomography; Response

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN; TUMOR MARKER;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DNA MICROARRAY; DYSPHAGIA; EARLY CANCER; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL ENDOSCOPY; GENE EXPRESSION PROFILING; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; NON INVASIVE MEASUREMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION RESPONSE; REVIEW; SYMPTOMATOLOGY; TREATMENT RESPONSE; TUMOR BIOPSY; WEIGHT GAIN; ADENOCARCINOMA; DIAGNOSTIC IMAGING; ESOPHAGEAL NEOPLASMS; LOWER ESOPHAGUS SPHINCTER; PATHOLOGY; SCINTISCANNING; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; DIAGNOSTIC IMAGING; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77950524690     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0293     Document Type: Review

References (88)

1. Brucher BL, Swisher SG, Königsrainer A et al. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 2009;16:878-886.
2. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002;359:1727-1733.
3. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007;8:226-234.
4. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
5. Kelsen DP, Winter KA, Gunderson LL et al. Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-3725.
6. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
7. Boige V, Pignon J, Saint-Aubert B et al. Final results of arandomizedtrial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07- FFCD 9703 trial. J Clin Oncol 2007;25(18 suppl):4510.
8. Koshy M, Esiashvilli N, Landry JC et al. Multiple management modalities in esophageal cancer: Epidemiology, presentation and progression, workup, and surgical approaches. The Oncologist 2004;9:137-146.
9. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
10. Rudiger Siewert J, Feith M, Werner M et al. Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/ topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353-361.
11. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
12. Meier I, Merkel S, Papadopoulos T et al. Adenocarcinoma of the esophagogastric junction: The pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition. Int J Radiat Oncol Biol Phys 2008;70:1408-1417.
13. Chau I, Norman AR, Cunningham D et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009;20:885-891.
14. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-4927.
15. Chung H, Bang YJ, Xu JM et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): Results of the ToGA trial screening programme and recommendations for HER2 testing. Eur J Cancer Suppl 2009; 7:6511.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Swisher SG, Maish M, Erasmus JJ et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-1160.
18. Flamen P, Van Cutsem E, Lerut A et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368.
19. Swisher SG, Erasmus J, Maish M et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-1785.
20. Brink I, Hentschel M, Bley TA et al. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 2004;30:544-550.
21. Wieder HA, Ott K, Lordick F et al. Prediction of tumor response by FDGPET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007;34:1925-1932.
22. Downey RJ, Akhurst T, Ilson D et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 2003;21:428-432.
23. Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
24. Kroep JR, Van Groeningen CJ, Cuesta MA et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 2003;5:337-346.
25. Ott K, Weber WA, Lordick F et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-4698.
26. Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007;8:797-805.
27. Gillham CM, Lucey JA, Keogan M et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-1179.
28. Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-4337.
29. Wu TT, Chirieac LR, Abraham SC et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome. Am J Surg Pathol 2007;31:58-64.
30. Brucher BL, Becker K, Lordick F et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006;106:2119-2127.
31. Becker K, Mueller JD, Schulmacher C et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530.
32. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-2686.
33. Salzer-Kuntschik M, Delling G, Beron G et al. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol 1983;106(suppl):21-24.
34. Junker K, Langner K, Klinke F et al. Grading of tumor regression in non-small cell lung cancer: Morphology and prognosis. Chest 2001;120:1584-1591.
35. Tepper JE, O'Neil B. Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. J Clin Oncol 2009;27:836-837.
36. Forshaw MJ, Gossage JA, Chrystal K et al. Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: Are they worth measuring? Clin Oncol (R Coll Radiol) 2006;18:345-350.
37. Brown WA, Thomas J, Gotley D et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004;91:199-204.
38. Jones DR, Parker LA Jr, Detterbeck FC et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:1026-1032.
39. Westerterp M, van Westreenen HL, Reitsma JB et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 2005;236:841-851.
40. 18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007;13:3460-3469.
41. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-3292.
42. Pauwels EK, Sturm EJ, Bombardieri E et al. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 2000;126:549-559.
43. van Westreenen HL, Plukker JT, Cobben DC et al. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 2005;185:436-440.
44. Lordick F, Ruers T, Aust DE et al. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 2008;44:1807-1819.
45. 18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688.
46. Weber WA, Petersen V, Schmidt B et al. Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657.
47. Abdel-Latif MM, O'Riordan J, Windle HJ et al. NFB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239:491-500.
48. Izzo JG, Malhotra U, Wu TT et al. Association of activated transcription factor nuclear factor B with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-754.
49. Izzo JG, Correa AM, Wu TT et al. Pretherapy nuclear factorB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 2006;5:2844-2850.
50. Gibson MK, Abraham SC, Wu TT et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003;9:6461-6468.
51. Schneider S, Uchida K, Brabender J et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005;200:336-344.
52. Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004;91:666-672.
53. Imdahl A, Bognar G, Schulte-Mönting J et al. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002;21:657-663.
54. Beardsmore DM, Verbeke CS, Davies CL et al. Apoptotic and proliferative indexes in esophageal cancer: Predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003;7:77-86; discussion 86-87.
55. Heeren PA, Kloppenberg FW, Hollema H et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004;24:2579-2583.
56. Warnecke-Eberz U, Metzger R, Miyazono F et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794-3799.
57. Joshi MB, Shirota Y, Danenberg KD et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-2221.
58. Warnecke-Eberz U, Hokita S, Xi H et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13:1241-1246.
59. Harpole DH Jr, Moore MB, Herndon JE 2nd et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001;7:562-569.
60. Langer R, Specht K, Becker K et al. Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouraciland cisplatin-based neoadjuvant chemotherapy. Am J Clin Pathol 2007;128:191-197.
61. Langer R, Specht K, Becker K et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11:7462-7469.
62. Abdel-Latif MM, O'Riordan JM, Ravi N et al. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis Esophagus 2005;18:246-252.
63. Kuwano H, Kato H, Miyazaki T et al. Genetic alterations in esophageal cancer. Surg Today 2005;35:7-18.
64. Reichelt U, Duesedau P, Tsourlakis MC et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-129.
65. Sgroi MM, Hanna NH, McCollum AD et al. Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal (GE) junction carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas-Southwestern. J Clin Oncol 2008;26(15 suppl):4564.
66. Safran H, DiPetrillo T, Akerman P et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67: 405-409.
67. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206.
68. Enzinger PC, Ryan DP, Regan EM et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 2008;26(15 suppl):4552.
69. Jhawer MP, Ilson D, Robinson E et al. Interim results of a phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GR) adenocarcinoma [abstract 109]. Presented at the American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
70. Sun W, Powell ME, O'Dwyer P et al. A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advancedunresectablegastricandgastroesophagealjunction(GEJ)adenocarcinoma (ECOG 5203). J Clin Oncol 2008;26(15 suppl):4535.
71. Luthra R, Wu TT, Luthra MG et al. Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-267.
72. Greenawalt DM, Duong C, Smyth GK et al. Gene expression profiling of esophageal cancer: Comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer 2007;120:1914-1921.
73. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97:1180-1184.
74. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
75. Cummings J, Ward TH, Greystoke A et al. Biomarker method validation in anticancer drug development. Br J Pharmacol 2008;153:646-656.
76. Cancer Research UK. Prognostic/Predictive Biomarker Roadmapguide to applying for a Cancer Research UK Biomarker. Available at http://science.cancerresearchuk.org/reps/pdfs/bidd_prognostic_roadmap.pdf, accessed October 9, 2009.
77. Pandeya N, Williams G, Green AC et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009;136:1215-1224.
78. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2006;17:38-44.
79. Siewert JR, Stein HJ, Feith M et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360-367.
80. Mariette C, Finzi L, Piessen G et al. Esophageal carcinoma: Prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 2005;29:39-45.
81. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
82. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
83. Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-1168.
84. Whiteman DC, Sadeghi S, Pandeya N et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008;57:173-180.
85. von Rahden BH, Stein HJ, Feith M. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005;23:874-879.
86. Derakhshan MH, Malekzadeh R, Watabe H et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008;57:298-305.
87. Aikou T, Shimazu H. Difference in main lymphatic pathways from the lower esophagus and gastric cardia. Jpn J Surg 1989;19:290-295.
88. Van Cutsem E, Van de Velde C, Roth A et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008;44:182-194.